glp-1 news today october 20 2025 Perspectives from employers on the costs and issues associated with covering agonists for weight loss Alarming rise in weight loss

Currently, tirzepatide is the most promising listed incretin analogue

Obesity GLP-1 Coverage and Weight Management Vendor Considerations Posted on June 25, 2024 2024 Trends in Drug Benefit Design Report Issue Brief Obesity is one of the largest public health concerns in the United States, as it affects over 40% of the adult population and is associated with various health conditions and poor health outcomes

Reported side effects include worsening of depression, anxiety, apathy, and, in rare cases suicidality, especially in populations using GLP-1RAs for weight loss without metabolic disease [30,42]

Platforms like MeAgain's GLP-1 app address this problem by combining no-markup compounded medications with daily tracking tools that build consistency over months